Literature DB >> 31167976

Dual muscle-liver transduction imposes immune tolerance for muscle transgene engraftment despite preexisting immunity.

Laurent Bartolo1, Stéphanie Li Chung Tong1, Pascal Chappert1, Dominique Urbain1, Fanny Collaud2, Pasqualina Colella2, Isabelle Richard2, Giuseppe Ronzitti2, Jocelyne Demengeot3, David A Gross1, Federico Mingozzi2, Jean Davoust1.   

Abstract

Immune responses to therapeutic transgenes are a potential hurdle to treat monogenic muscle disorders. These responses result from the neutralizing activity of transgene-specific B cells and cytotoxic T cells recruited upon gene transfer. We explored here how dual muscle-liver expression of a foreign transgene allows muscle transgene engraftment after adenoassociated viral vector delivery. We found in particular that induction of transgene-specific tolerance is imposed by concurrent muscle and liver targeting, resulting in the absence of CD8+ T cell responses to the transgene. This tolerance can be temporally decoupled, because transgene engraftment can be achieved in muscle weeks after liver transduction. Importantly, transgene-specific CD8+ T cell tolerance can be established despite preexisting immunity to the transgene. Whenever preexisting, transgene-specific CD4+ and CD8+ memory T cell responses are present, dual muscle-liver transduction turns polyclonal, transgene-specific CD8+ T cells into typically exhausted T cells with high programmed cell death 1 (PD-1) expression and lack of IFN-γ production. Our results demonstrate that successful transduction of muscle tissue can be achieved through liver-mediated control of humoral and cytotoxic T cell responses, even in the presence of preexisting immunity to the muscle-associated transgene.

Entities:  

Keywords:  Adaptive immunity; Gene therapy; Immunology; T cells

Year:  2019        PMID: 31167976      PMCID: PMC6629094          DOI: 10.1172/jci.insight.127008

Source DB:  PubMed          Journal:  JCI Insight        ISSN: 2379-3708


  55 in total

1.  Synthetic muscle promoters: activities exceeding naturally occurring regulatory sequences.

Authors:  X Li; E M Eastman; R J Schwartz; R Draghia-Akli
Journal:  Nat Biotechnol       Date:  1999-03       Impact factor: 54.908

2.  AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of alpha-galactosidase A and the induction of immune tolerance in Fabry mice.

Authors:  Robin J Ziegler; Scott M Lonning; Donna Armentano; Chester Li; David W Souza; Maribeth Cherry; Christine Ford; Christine M Barbon; Robert J Desnick; Guangping Gao; James M Wilson; Richard Peluso; Simon Godwin; Barrie J Carter; Richard J Gregory; Samuel C Wadsworth; Seng H Cheng
Journal:  Mol Ther       Date:  2004-02       Impact factor: 11.454

3.  Major role of local immune responses in antibody formation to factor IX in AAV gene transfer.

Authors:  L Wang; O Cao; B Swalm; E Dobrzynski; F Mingozzi; R W Herzog
Journal:  Gene Ther       Date:  2005-10       Impact factor: 5.250

4.  Adeno-associated virus vector-mediated gene transfer into dystrophin-deficient skeletal muscles evokes enhanced immune response against the transgene product.

Authors:  K Yuasa; M Sakamoto; Y Miyagoe-Suzuki; A Tanouchi; H Yamamoto; J Li; J S Chamberlain; X Xiao; S Takeda
Journal:  Gene Ther       Date:  2002-12       Impact factor: 5.250

5.  Risk and prevention of anti-factor IX formation in AAV-mediated gene transfer in the context of a large deletion of F9.

Authors:  P A Fields; V R Arruda; E Armstrong; K Chu; F Mingozzi; J N Hagstrom; R W Herzog; K A High
Journal:  Mol Ther       Date:  2001-09       Impact factor: 11.454

6.  Delivery of alpha- and beta-sarcoglycan by recombinant adeno-associated virus: efficient rescue of muscle, but differential toxicity.

Authors:  D Dressman; K Araishi; M Imamura; T Sasaoka; L A Liu; E Engvall; E P Hoffman
Journal:  Hum Gene Ther       Date:  2002-09-01       Impact factor: 5.695

7.  Passive and active mechanisms trap activated CD8+ T cells in the liver.

Authors:  Beena John; Ian Nicholas Crispe
Journal:  J Immunol       Date:  2004-05-01       Impact factor: 5.422

8.  Induction of immune tolerance to coagulation factor IX antigen by in vivo hepatic gene transfer.

Authors:  Federico Mingozzi; Yi-Lin Liu; Eric Dobrzynski; Antje Kaufhold; Jian Hua Liu; YuQin Wang; Valder R Arruda; Katherine A High; Roland W Herzog
Journal:  J Clin Invest       Date:  2003-05       Impact factor: 14.808

9.  The site of primary T cell activation is a determinant of the balance between intrahepatic tolerance and immunity.

Authors:  David G Bowen; Monica Zen; Lauren Holz; Thomas Davis; Geoffrey W McCaughan; Patrick Bertolino
Journal:  J Clin Invest       Date:  2004-09       Impact factor: 14.808

10.  Identification of an HLA-A*0201-restricted epitopic peptide from human dystrophin: application in duchenne muscular dystrophy gene therapy.

Authors:  F Ginhoux; C Doucet; M Leboeuf; F A Lemonnier; O Danos; J Davoust; H Firat
Journal:  Mol Ther       Date:  2003-08       Impact factor: 11.454

View more
  10 in total

Review 1.  AAV Vector Immunogenicity in Humans: A Long Journey to Successful Gene Transfer.

Authors:  Helena Costa Verdera; Klaudia Kuranda; Federico Mingozzi
Journal:  Mol Ther       Date:  2020-01-10       Impact factor: 11.454

Review 2.  Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery.

Authors:  Natalie F Nidetz; Michael C McGee; Longping V Tse; Chengwen Li; Le Cong; Yunxing Li; Weishan Huang
Journal:  Pharmacol Ther       Date:  2019-12-11       Impact factor: 12.310

Review 3.  Human Immune Responses to Adeno-Associated Virus (AAV) Vectors.

Authors:  Giuseppe Ronzitti; David-Alexandre Gross; Federico Mingozzi
Journal:  Front Immunol       Date:  2020-04-17       Impact factor: 7.561

4.  Long-Term Delivery of an Anti-SIV Monoclonal Antibody With AAV.

Authors:  José M Martinez-Navio; Sebastian P Fuchs; Desiree E Mendes; Eva G Rakasz; Guangping Gao; Jeffrey D Lifson; Ronald C Desrosiers
Journal:  Front Immunol       Date:  2020-03-17       Impact factor: 7.561

5.  Role of Regulatory T Cell and Effector T Cell Exhaustion in Liver-Mediated Transgene Tolerance in Muscle.

Authors:  Jérôme Poupiot; Helena Costa Verdera; Romain Hardet; Pasqualina Colella; Fanny Collaud; Laurent Bartolo; Jean Davoust; Peggy Sanatine; Federico Mingozzi; Isabelle Richard; Giuseppe Ronzitti
Journal:  Mol Ther Methods Clin Dev       Date:  2019-09-03       Impact factor: 6.698

Review 6.  Adeno-Associated Viruses (AAV) and Host Immunity - A Race Between the Hare and the Hedgehog.

Authors:  Kleopatra Rapti; Dirk Grimm
Journal:  Front Immunol       Date:  2021-10-29       Impact factor: 7.561

7.  Hepatic expression of GAA results in enhanced enzyme bioavailability in mice and non-human primates.

Authors:  Helena Costa-Verdera; Fanny Collaud; Christopher R Riling; Pauline Sellier; Jayme M L Nordin; G Michael Preston; Umut Cagin; Julien Fabregue; Simon Barral; Maryse Moya-Nilges; Jacomina Krijnse-Locker; Laetitia van Wittenberghe; Natalie Daniele; Bernard Gjata; Jeremie Cosette; Catalina Abad; Marcelo Simon-Sola; Severine Charles; Mathew Li; Marco Crosariol; Tom Antrilli; William J Quinn; David A Gross; Olivier Boyer; Xavier M Anguela; Sean M Armour; Pasqualina Colella; Giuseppe Ronzitti; Federico Mingozzi
Journal:  Nat Commun       Date:  2021-11-04       Impact factor: 14.919

8.  Chimeric Mice Engrafted With Canine Hepatocytes Exhibits Similar AAV Transduction Efficiency to Hemophilia B Dog.

Authors:  Wenwei Shao; Junjiang Sun; Xiaojing Chen; Amanda Dobbins; Elizabeth P Merricks; R Jude Samulski; Timothy C Nichols; Chengwen Li
Journal:  Front Pharmacol       Date:  2022-01-31       Impact factor: 5.810

9.  Neuropilin-1 cooperates with PD-1 in CD8+ T cells predicting outcomes in melanoma patients treated with anti-PD1.

Authors:  Julien Rossignol; Zakia Belaid; Guillemette Fouquet; Flavia Guillem; Rachel Rignault; Pierre Milpied; Amédée Renand; Tereza Coman; Maud D'Aveni; Michael Dussiot; Elia Colin; Jonathan Levy; Caroline Carvalho; Nicolas Goudin; Nicolas Cagnard; Francine Côté; Joel Babdor; Kanit Bhukhai; Laura Polivka; Amélie E Bigorgne; Héloise Halse; Aurélien Marabelle; Séverine Mouraud; Yves Lepelletier; Thiago T Maciel; Marie-Thérèse Rubio; Delphine Heron; Caroline Robert; Isabelle Girault; Doris Lebeherec; Jean-Yves Scoazec; Ivan Moura; Louise Condon; Mirjana Weimershaus; Franck Pages; Jean Davoust; David Gross; Olivier Hermine
Journal:  iScience       Date:  2022-05-05

10.  Enhancement of the Tolerogenic Phenotype in the Liver by ImmTOR Nanoparticles.

Authors:  Petr O Ilyinskii; Christopher J Roy; Julie LePrevost; Gina L Rizzo; Takashi Kei Kishimoto
Journal:  Front Immunol       Date:  2021-05-25       Impact factor: 7.561

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.